Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 203

Results For "NDA"

3699 News Found

Lupin launches novel fixed-dose triple drug combination DIFIZMA DPI to treat Asthma
News | January 06, 2023

Lupin launches novel fixed-dose triple drug combination DIFIZMA DPI to treat Asthma

The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05% and out of this, approximately 30 lakh patients can be classified under “inadequately controlled”


Applied Therapeutics partners with Advanz Pharma for commercialization of Govorestat in Europe
Biotech | January 05, 2023

Applied Therapeutics partners with Advanz Pharma for commercialization of Govorestat in Europe

Advanz Pharma will leverage its specialty, hospital, and rare disease expertise and infrastructure to commercialize AT-007 in Europe for both Galactosemia and SORD Deficiency


Viatris acquires Oyster Point Pharma and Famy Life Sciences
Healthcare | January 05, 2023

Viatris acquires Oyster Point Pharma and Famy Life Sciences

Acquisitions have the potential to add at least $1 billion in sales by 2028


Briefs: Gland Pharma, Supriya Lifescience, Hindustan Unilever and Eugia Pharma
Drug Approval | January 05, 2023

Briefs: Gland Pharma, Supriya Lifescience, Hindustan Unilever and Eugia Pharma

Supriya Lifescience Limited has informed that the European Directorate for the Quality of Medicines (EDQM) has granted Attestation of Inspection (EU-GMP) for Lote API Facility, Ratnagiri, Maharashtra.


IIT Kanpur and Apollo Hospitals join hands for research collaboration
News | January 04, 2023

IIT Kanpur and Apollo Hospitals join hands for research collaboration

The collaboration with IIT Kanpur will build on this foundation and expand the domain of research and development in healthcare technology


BDR Pharmaceutical launches the first generic to treat Prostate cancer in India
News | January 04, 2023

BDR Pharmaceutical launches the first generic to treat Prostate cancer in India

BDRs journey for the treatment of Prostate Cancer started with Abiratarone Acetate, then Leuprolide Acetate followed by Enzalutamide and, then Degarelix and Triptorelin.


MoU signed for commercial production of indigenously developed vaccine ‘Lumpi-ProVac’
Policy | January 02, 2023

MoU signed for commercial production of indigenously developed vaccine ‘Lumpi-ProVac’

Lumpi-ProVacind is used for the prophylactic immunization of animals against Lumpy Skin Disease, which illicit protection for about one year


Survival Technologies files DRHP with SEBI for Rs 1,000 crore IPO
News | January 02, 2023

Survival Technologies files DRHP with SEBI for Rs 1,000 crore IPO

The company is one of the most profitable companies manufacturing speciality chemicals in India


Quantori partners with Databricks to accelerate data-driven innovation in life sciences
Digitisation | January 02, 2023

Quantori partners with Databricks to accelerate data-driven innovation in life sciences

Quantori develops solutions on the Databricks Lakehouse Platform providing real-time insights


Aster DM Healthcare inks O&M agreement to operate hospital in Mandya
Healthcare | January 01, 2023

Aster DM Healthcare inks O&M agreement to operate hospital in Mandya

The term of O&M is for 15 years with a lock in period of 5 years for the Company and 15 years for VHPL & Bharathi Education trust.